manumycin A

Manumycin A is a naturally occurring polyketide antibiotic isolated from *Streptomyces parvulus* that serves as a potent and selective inhibitor of farnesyltransferase (FTase). By inhibiting FTase, it prevents the farnesylation and subsequent membrane attachment of Ras proteins, thereby disrupting Ras-mediated signaling pathways. Beyond its primary role as an FTase inhibitor, manumycin A also targets thioredoxin reductase 1 (TrxR-1) and IkappaB kinase (IKK). Preclinical research has demonstrated its potential anticancer efficacy across various malignancies, including triple-negative breast, colorectal, and pancreatic cancers, through mechanisms such as apoptosis induction and inhibition of PI3K-AKT and Ras/Raf/ERK1/2 pathways. It also exhibits anti-inflammatory properties and has shown promise in correcting splicing defects in models of myotonic dystrophy type 1. Currently, it is utilized primarily as a research tool and is not in active clinical development by a pharmaceutical sponsor.

Other names

manumycin A